IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:		plication of:	Group Art Unit: 1657	
	SCH	MIDT	Confirmation No.: 7191	
Serial	No.: 1	0/655,889) Examiner: Afremova, V.	
Filed: September 4, 2003			SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	
Atty. File No.: 5662-1-PUS-1-1				
For:	THEI URO DISO	OF NEUROTOXIN RAPY FOR TREATMENT OF) LOGICAL-NEUROLOGICAL) RDERS ASSSOCATED H PROSTATE CANCER"		
Comn P.O. E	nissione Box 145	mendment er for Patents 50 VA 22313-1450		
Dear S	Sir:			
	The re	eferences cited on attached Form	n PTO-SB08 are being called to the attention of the	
Exam	iner.			
	\boxtimes	Copies of the cited non-patent	and/or foreign references are enclosed herewith.	
		Copies of the cited U.S. patent	s and/or patent applications are enclosed herewith.	
	\boxtimes	Copies of the cited U.S. patent	s/patent application publications are not enclosed in	
accord	lance w	rith 37 C.F.R. § 1.98(a).		
		Copies of the cited reference	s are not enclosed, in accordance with 37 C.F.R.	
§ 1.98	(d), bec	ause the references were cited by	or submitted to the U.S. Patent and Trademark Office	
		cation Serial No f date under 35 U.S.C. § 120.	iled, which is relied upon for an	
	\boxtimes	To the best of applicants' belief,	, the pertinence of the foreign-language references are	
believ	ed to be	summarized in the attached Eng	glish abstracts and in the figures, although applicants	
do not	necess	arily vouch for the accuracy of the	ne translation.	

⊠	Examiner's attention is drawn to the following co-pending applications:
	Serial No. 10/778924 filed 02-13-2004, now U.S. Patent Publication No.
2005/0048084	(Attorney's Ref. No. 5662-1-PUS-1-2);
	Serial No. 10/778948 filed 02-13-2004, now U.S. Patent Publication No.
2005/0049175	(Attorney's Ref. No. 5662-1-PUS-1-3);
	Serial No. 10/981015 filed 11-03-2004, now U.S. Patent Publication No.
2005/0112147	(Attorney's Ref. No. 5662-1-PUS-1-6);
	Serial No. 11/077895 filed 03-11-2005, now U.S. Patent Publication No.
2005/0159337	(Attorney's Ref. No. 5662-1-PUS-1-7);
	Serial No. $\underline{11/925938}$ filed $\underline{10\text{-}27\text{-}2007}$ (Attorney's Ref. No. 5662-1-PUS-1-8);
	Serial No. $\underline{11/925942}$ filed $\underline{10\text{-}27\text{-}2007}$ (Attorney's Ref. No. 5662-1-PUS-1-9);
	Serial No. <u>11/925945</u> filed <u>10-27-2007</u> (Attorney's Ref. No. 5662-1-PUS-1-10):
	Other:

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

		37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfies one of the following conditions ("X" indicates satisfaction):		
			Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or	
			Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or	
			Before the mailing date of a first Office Action on the merits, or	
		⊠	Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114.	
		Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.		

	37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by: A Certification (below) as specified by 37 C.F.R. 1.97(c). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p)
	for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.
П	37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).
	☐ This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND
	☐ Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit
	Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or
	charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.
	Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)
	The undersigned certifies that:
	☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).
	any communication from a foreign patent office in a counterpart foreign application not more than
	any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).

Respectfully submitted,

SHERIDAN ROSS P.C.

Darla G. Yoerg

Registration No. 48,053 1560 Broadway, Suite 1200

Denver, Colorado 80202-5141

(303) 863-9700